|
🐜
|
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
16 auth.
C. Caussy,
A. Tripathi,
G. Humphrey,
Shirin Bassirian,
Seema Singh,
Claire S. Faulkner,
R. Bettencourt,
E. Rizo,
L. Richards,
Z. Xu,
...
M. Downes,
R. Evans,
D. Brenner,
C. Sirlin,
R. Knight,
R. Loomba
|
7 |
2019 |
7
🐜
|
|
🐜
|
An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
11 auth.
Peng Zhao,
Xiaoli Sun,
Cynthia Chaggan,
Z. Liao,
Kai In Wong,
Feng He,
...
Seema Singh,
R. Loomba,
M. Karin,
J. Witztum,
A. Saltiel
|
7 |
2020 |
7
🐜
|
|
🐜
|
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.
21 auth.
Tae Gyu Oh,
Susy M Kim,
C. Caussy,
T. Fu,
Jian Guo,
Shirin Bassirian,
Seema Singh,
Egbert Madamba,
R. Bettencourt,
L. Richards,
...
M. Raffatellu,
P. Dorrestein,
R. Yu,
A. Atkins,
T. Huan,
D. Brenner,
C. Sirlin,
R. Knight,
M. Downes,
R. Evans,
R. Loomba
|
7 |
2020 |
7
🐜
|
|
🐜
|
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
17 auth.
Veeral H. Ajmera,
Charlie C. Park,
C. Caussy,
Seema Singh,
C. Hernandez,
R. Bettencourt,
J. Hooker,
Ethan Sy,
C. Behling,
R. Xu,
...
M. Middleton,
M. Valasek,
Claire S. Faulkner,
E. Rizo,
L. Richards,
C. Sirlin,
R. Loomba
|
6 |
2018 |
6
🐜
|
|
🐜
|
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis
15 auth.
Jinho Jung,
R. Loomba,
Kento Imajo,
Egbert Madamba,
Sanil Gandhi,
R. Bettencourt,
Seema Singh,
C. Hernandez,
M. Valasek,
C. Behling,
...
L. Richards,
Katie Fowler,
C. Sirlin,
A. Nakajima,
R. Loomba
|
6 |
2020 |
6
🐜
|
|
🐜
|
Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose‐dependent changes with increase in fibrosis stage in patients with biopsy‐proven NAFLD
15 auth.
C. Caussy,
Cynthia L. Hsu,
Seema Singh,
Shirin Bassirian,
J. Kolar,
Claire S. Faulkner,
Nikhil Sinha,
R. Bettencourt,
Naveen Gara,
M. Valasek,
...
B. Schnabl,
L. Richards,
D. Brenner,
A. Hofmann,
R. Loomba
|
6 |
2018 |
6
🐜
|
|
🐜
|
Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease
16 auth.
Veeral H. Ajmera,
Amy Liu,
Seema Singh,
Georg Yachoa,
Matthew Ramey,
Meera Bhargava,
Ava Zamani,
Scarlett J. Lopez,
N. Mangla,
R. Bettencourt,
...
E. Rizo,
M. Valasek,
C. Behling,
L. Richards,
C. Sirlin,
R. Loomba
|
5 |
2020 |
5
🐜
|
|
🐜
|
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
15 auth.
C. Caussy,
Veeral H. Ajmera,
P. Puri,
Cynthia L. Hsu,
Shirin Bassirian,
Mania Mgdsyan,
Seema Singh,
Claire S. Faulkner,
M. Valasek,
E. Rizo,
...
L. Richards,
D. Brenner,
C. Sirlin,
A. Sanyal,
R. Loomba
|
5 |
2018 |
5
🐜
|
|
🐜
|
MRI Assessment of Treatment Response in HIV‐associated NAFLD: A Randomized Trial of a Stearoyl‐Coenzyme‐A‐Desaturase‐1 Inhibitor (ARRIVE Trial)
19 auth.
Veeral H. Ajmera,
E. Cachay,
C. Ramers,
Irine Vodkin,
Shirin Bassirian,
Seema Singh,
N. Mangla,
R. Bettencourt,
Jeannette L. Aldous,
Daniel Park,
...
Daniel Lee,
Jennifer N Blanchard,
A. Mamidipalli,
A. Boehringer,
S. Aslam,
O. Leinhard,
L. Richards,
C. Sirlin,
R. Loomba
|
5 |
2019 |
5
🐜
|
|
🐜
|
Prospective, Same-day, Direct Comparison of CAP With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Standard.
10 auth.
C. Caussy,
Justine Brissot,
Seema Singh,
Shirin Bassirian,
C. Hernandez,
R. Bettencourt,
...
E. Rizo,
L. Richards,
C. Sirlin,
R. Loomba
|
5 |
2019 |
5
🐜
|
